Table 3

Time to grade 2 or higher bleeding

CharacteristicN% censoredHazard ratio95% CIP
Randomized treatment group     .77 (2 df
    LD 247 51.0 1.00 0.77-1.30 .99 
    MD 251 54.2 Referent category   
    HD 280 47.5 1.08 0.84-1.39 .54 
Platelet source     .44 
    Apheresis 552 54.5 Referent category   
    WBP 220 53.2 1.15 0.81-1.65 .44 
ABO matching status     .33 (2 df
    ABO-identical 467 64.2 Referent category   
    Minor mismatch 75 76.0 0.85 0.52-1.40 .52 
    Major mismatch 198 75.8 0.78 0.56-1.09 .15 
Storage duration, d     .87 (3 df
    0-2 48 83.3 0.86 0.39-1.87 .70 
    3 158 79.8 Referent category   
    4 223 81.2 1.03 0.64-1.64 .91 
    5 221 77.8 1.13 0.72-1.79 .59 
CharacteristicN% censoredHazard ratio95% CIP
Randomized treatment group     .77 (2 df
    LD 247 51.0 1.00 0.77-1.30 .99 
    MD 251 54.2 Referent category   
    HD 280 47.5 1.08 0.84-1.39 .54 
Platelet source     .44 
    Apheresis 552 54.5 Referent category   
    WBP 220 53.2 1.15 0.81-1.65 .44 
ABO matching status     .33 (2 df
    ABO-identical 467 64.2 Referent category   
    Minor mismatch 75 76.0 0.85 0.52-1.40 .52 
    Major mismatch 198 75.8 0.78 0.56-1.09 .15 
Storage duration, d     .87 (3 df
    0-2 48 83.3 0.86 0.39-1.87 .70 
    3 158 79.8 Referent category   
    4 223 81.2 1.03 0.64-1.64 .91 
    5 221 77.8 1.13 0.72-1.79 .59 

Adjusted frailty models of days from first platelet transfusion to ≥ grade 2 bleeding. Hazard ratios > 1.00 indicate higher risk of bleeding in patients receiving platelets with the specified characteristic compared with patients receiving platelets with the reference characteristic. Each model includes one platelet characteristic (randomized dose assignment, source, matching status, or storage duration) and is also adjusted for patient sex, patient age group, patient treatment category, and site (with site treated as a random effect). Data on time to bleeding were censored if any of the following occurred before the patient experienced grade 2 or higher bleeding: a transfusion that differed from the patient's first transfusion in the characteristic being analyzed or had missing data on that characteristic; a day with missing data on whether grade 2 or higher bleeding had occurred; or end of study.

N indicates number of evaluable patients; LD, low dose; MD, medium dose; HD, high dose; and WBP, whole blood platelet pools.

or Create an Account

Close Modal
Close Modal